Novavax Stock News

The stock price of Novavax (NASDAQ: NVAX), a Covid-19 vaccine developer, trades at $13 per share, about 96% below its peak level of $320 seen in February 2021. NVAX stock was trading at around $51 in

The meme stock season seems to be back. Novavax (NASDAQ: NVAX ) has surged over 200% in the last month, with big gains coming in a few trading days.

Moderna's sales soared into the billions as it conquered the coronavirus vaccine market -- and today the company promises to deliver many new products in the near term. Novavax struggled in recent tim

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ:NVAX). The settlem

The S&P 500 is on the longest streak since February, partly buoyed by stocks with analyst upgrades. The Dow Jones Industrial Average is also increasing amid mixed economic signals, as consumer sentime

The vaccine developer's shares got a hefty pop on the announcement of a collaboration deal. In the mind of one pundit tracking the stock, however, this means the shares are now fairly valued, and migh

Growth stocks have been steadily marching higher since the 2008 financial crisis. Even so, there are still plenty of compelling bargains in the space.

Novavax just eliminated its biggest risk thanks to a billion-dollar deal with pharma giant Sanofi. The agreement could also boost long-term growth.

NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ:NVAX). The settlem

The biotech industry is notably risky, but can produce stocks that see massive gains within a day. How can this happen?

No, it's not 2021. But waking up today, you might have been forgiven for thinking so.

Meme stocks have the potential to completely change the portfolio health even with a limited exposure of 5% to 10%. The best example now is Carvana (NYSE: CVNA ), which surged from under-$5 levels at

Novavax stock more than doubled in response to a licensing deal with a big pharma partner. Sanofi will give Novavax $500 million up front to co-license and co-commercialize its COVID-19 vaccine.

GAITHERSBURG, Md. , May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in

Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.